Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806325 | 0.80 | MAPT (0.69) | MAPTDDB1CRBNGPR119PTPN11 | |
| SCHEMBL31598300 | 0.76 | MAPT (0.60) | MAPTDDB1CRBNGPR119NR1H2 | |
| SCHEMBL24421291 | 0.75 | MAPT (0.46) | MAPTDDB1CRBNGPR119NAMPT | |
| SCHEMBL21528005 | 0.75 | MAPT (0.64) | MAPTDDB1CRBNNR1H2 | |
| SCHEMBL21528192 | 0.75 | MAPT (0.64) | MAPTDDB1CRBNNR1H2 | |
| SCHEMBL21528022 | 0.75 | MAPT (0.64) | MAPTDDB1CRBNNR1H2 | |
| SCHEMBL18818488 | 0.75 | DDB1 (0.53) | MAPTDDB1CRBNGPR119NAMPT | |
| SCHEMBL20078108 | 0.75 | DDB1 (0.53) | MAPTDDB1CRBNNR1H2 | |
| SCHEMBL22503993 | 0.74 | DDB1 (0.51) | MAPTDDB1CRBNGPR119NAMPT | |
| SCHEMBL22165425 | 0.74 | DDB1 (0.51) | MAPTDDB1CRBNGPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |